Sabby Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Sabby Management’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Hold	–	-$88K	–	374
2015 Q3	–	Hold	–	–	–	367
2015 Q2	–	Hold	–	–	–	306
2015 Q1	–	Hold	–	–	–	278
2014 Q4	–	Hold	–	-$130	–	286
2014 Q3	–	Hold	–	–	–	230
2014 Q2	–	Hold	–	–	–	205
2014 Q1	–	Hold	–	–	–	197
2013 Q4	–	Hold	–	–	–	173
2013 Q3	–	Hold	–	–	–	183

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's SEEL Position: Q4 2023 in Review

Sabby Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 3,071 shares — an estimated $2.17M sold.

Sabby Management first reported a position in SEEL in Q1 2018 and held it in 4 quarters. The position peaked at $2.17M in Q3 2023. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

Sabby Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Sabby Management sold 3,071 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.17M.
Sabby Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2018 and held it in 4 quarters.
Sabby Management's Seelos Therapeutics, Inc. Common Stock position peaked at $2.17M in Q3 2023.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.